glp 1 and ssri Psychotropic effects of GLP-1R agonists Evolution of GLP‐1 Receptor Agonists

Analogs of MOTS-c are being developed by pharmaceutical companies for obesity and fatty liver disease, confirming significant translational interest

Semaglutide (Wegovy, Ozempic) received FDA approval for chronic weight management in 2021, followed by tirzepatide (Zepbound) in 2023, both demonstrating substantial weight loss in clinical trials

It allows them to slide into our biological processes more seamlessly, sending signals to cells to regulate and rejuvenate functions that might be waning due to age or illness

Relationship between plasma homocysteine and chronic kidney disease in US patients with type 2 diabetes mellitus: a cross-sectional study

The Evolution: Tirzepatide's Dual-Agonist Advantage Tirzepatide represents a major evolutionary step forward in metabolic support by operating as a "twincretin." In addition to stimulating the GLP-1 receptor, it simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP) pathway